Hiroshi Nagabukuro

612 total citations
22 papers, 260 citations indexed

About

Hiroshi Nagabukuro is a scholar working on Urology, Epidemiology and Molecular Biology. According to data from OpenAlex, Hiroshi Nagabukuro has authored 22 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Urology, 7 papers in Epidemiology and 5 papers in Molecular Biology. Recurrent topics in Hiroshi Nagabukuro's work include Urinary Bladder and Prostate Research (10 papers), Urinary Tract Infections Management (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). Hiroshi Nagabukuro is often cited by papers focused on Urinary Bladder and Prostate Research (10 papers), Urinary Tract Infections Management (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). Hiroshi Nagabukuro collaborates with scholars based in Japan, United States and United Kingdom. Hiroshi Nagabukuro's co-authors include Karen J. Berkley, Takayuki Doi, Natalia Dmitrieva, Tadatoshi Hashimoto, David Resuehr, Yukari Takeuchi, Ken Mackie, Stacy L. McAllister, Guohua Zhang and Yuji Mori and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Pain and Journal of Medicinal Chemistry.

In The Last Decade

Hiroshi Nagabukuro

21 papers receiving 257 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroshi Nagabukuro Japan	10	78	75	40	40	37	22	260
Tiina Dietz Germany	6	343 4.4×	15 0.2×	18 0.5×	59 1.5×	176 4.8×	8	465
Qiyun Yang China	10	159 2.0×	77 1.0×	10 0.3×	10 0.3×	119 3.2×	22	376
Sumika Matsui Japan	11	153 2.0×	6 0.1×	13 0.3×	45 1.1×	86 2.3×	31	374
Anna‐Karin Lind Sweden	8	217 2.8×	14 0.2×	50 1.3×	4 0.1×	157 4.2×	12	340
Paul S. Weathersbee United States	9	99 1.3×	6 0.1×	48 1.2×	18 0.5×	153 4.1×	17	344
Yuelai Chen China	10	40 0.5×	61 0.8×	54 1.4×	23 0.6×	40 1.1×	68	280
Ali Aflatounian Australia	8	194 2.5×	13 0.2×	9 0.2×	10 0.3×	134 3.6×	14	307
Hong N. Bui Netherlands	11	98 1.3×	19 0.3×	21 0.5×	9 0.2×	39 1.1×	14	402
S Holland United Kingdom	9	108 1.4×	30 0.4×	6 0.1×	15 0.4×	51 1.4×	17	345
Valeria Tagliaferri Italy	12	239 3.1×	8 0.1×	11 0.3×	8 0.2×	139 3.8×	18	338

Countries citing papers authored by Hiroshi Nagabukuro

Since Specialization

Citations

This map shows the geographic impact of Hiroshi Nagabukuro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Nagabukuro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Nagabukuro more than expected).

Fields of papers citing papers by Hiroshi Nagabukuro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Nagabukuro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Nagabukuro. The network helps show where Hiroshi Nagabukuro may publish in the future.

Co-authorship network of co-authors of Hiroshi Nagabukuro

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Nagabukuro. A scholar is included among the top collaborators of Hiroshi Nagabukuro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Nagabukuro. Hiroshi Nagabukuro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ozeki, Michio, Akira Tanaka, Taiki Nozaki, et al.. (2025). A phase 2 randomized, double-blind trial of ART-001, a selective PI3Kα inhibitor, for the treatment of slow-flow vascular malformations. Orphanet Journal of Rare Diseases. 20(1). 64–64.

Nagabukuro, Hiroshi, et al.. (2024). Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study. Clinical and Translational Science. 17(10). e70024–e70024. 1 indexed citations

Tanaka, Akira, et al.. (2023). A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of ART‐001 with a novel oral pediatric formulation in healthy subjects. Clinical and Translational Science. 16(10). 1898–1910. 2 indexed citations

Ohata, Keiichi, Takeshi Sugaya, Tsuyoshi Oikawa, et al.. (2023). Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury. Nephrology. 29(3). 117–125. 3 indexed citations

Ohata, Keiichi, Takeshi Sugaya, Tsuyoshi Oikawa, et al.. (2023). Urinary liver‐type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone. Nephrology. 28(6). 345–355. 3 indexed citations

Makabe, Tomoko, Kaori Koga, Hiroshi Nagabukuro, et al.. (2020). Use of selective PGE2 receptor antagonists on human endometriotic stromal cells and peritoneal macrophages. Molecular Human Reproduction. 27(1). 10 indexed citations

Amano, Yuichiro, Mayumi Imai, Kimio Tohyama, et al.. (2018). Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochemical and Biophysical Research Communications. 497(1). 207–213. 8 indexed citations

Amano, Yuichiro, et al.. (2016). Non‐alcoholic steatohepatitis‐associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge. Hepatology Research. 47(1). 103–115. 9 indexed citations

Kohara, Yasuhisa, Yumi Imai, Hiroshi Nagabukuro, et al.. (2016). Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α_1DAdrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities. Journal of Medicinal Chemistry. 59(7). 2989–3002. 4 indexed citations

10.

Nagabukuro, Hiroshi, L. Alexandra Wickham, Marcie J. Donnelly, et al.. (2011). Comparative Analysis of the Effects of Antimuscarinic Agents on Bladder Functions in Both Nonhuman Primates and Rodents. Journal of Pharmacology and Experimental Therapeutics. 338(1). 220–227. 9 indexed citations

11.

Nagabukuro, Hiroshi, et al.. (2010). Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats. Autonomic Neuroscience. 156(1-2). 19–26. 7 indexed citations

12.

Dmitrieva, Natalia, Hiroshi Nagabukuro, David Resuehr, et al.. (2010). Endocannabinoid involvement in endometriosis. Pain. 151(3). 703–710. 45 indexed citations

13.

Dmitrieva, Natalia, Guohua Zhang, & Hiroshi Nagabukuro. (2008). Increased α1D adrenergic receptor activity and protein expression in the urinary bladder of aged rats. World Journal of Urology. 26(6). 649–655. 11 indexed citations

14.

Nagabukuro, Hiroshi & Karen J. Berkley. (2007). Influence of endometriosis on visceromotor and cardiovascular responses induced by vaginal distention in the rat. Pain. 132(Supplement 1). S96–S103. 39 indexed citations

15.

Nagabukuro, Hiroshi, Tadatoshi Hashimoto, Masashi Iwata, & Takayuki Doi. (2005). Effects of TAK‐802, a novel acetylcholinesterase inhibitor, and tamsulosin, an α ₁ ‐adrenoceptor antagonist, and their synergistic effects on the urodynamic characteristics in a guinea‐pig model of functional bladder outlet obstruction. British Journal of Urology. 95(7). 1071–1076. 7 indexed citations

16.

Nagabukuro, Hiroshi & Takayuki Doi. (2005). Differential effects of TAK-802, a selective acetylcholinesterase inhibitor, and carbamate acetylcholinesterase inhibitors on contraction of the detrusor smooth muscle of the guinea pig. Life Sciences. 77(26). 3276–3286. 6 indexed citations

17.

Ishichi, Yuji, Mitsuru Sasaki, Tetsuya Tsukamoto, et al.. (2005). Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds. Bioorganic & Medicinal Chemistry. 13(6). 1901–1911. 15 indexed citations

18.

Hashimoto, Tadatoshi, Hiroshi Nagabukuro, & Takayuki Doi. (2005). EFFECTS OF THE SELECTIVE ACETYLCHOLINESTERASE INHIBITOR TAK-802 ON THE VOIDING BEHAVIOR AND BLADDER MASS INCREASE IN RATS WITH PARTIAL BLADDER OUTLET OBSTRUCTION. The Journal of Urology. 174(3). 1137–1141. 22 indexed citations

19.

Nagabukuro, Hiroshi, et al.. (2004). Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs. European Journal of Pharmacology. 494(2-3). 225–232. 15 indexed citations

20.

Nagabukuro, Hiroshi, et al.. (2003). Effects of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rats and guinea pigs. European Journal of Pharmacology. 485(1-3). 299–305. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact